The good and the good for 2017: how results of the SWOG 0777 trial and serum Freelite testing can help myeloma patients

I often discuss the good and the bad in the news. But I thought it would be great to start 2017 with just the good! The SWOG 0777 trial results, recently published in The Lancet, and serum Freelite testing, just published in Blood, will help day-to-day care of myeloma patients in a variety of ways. Both studies are considered important and have accompanying commentaries or editorials in the journals reflecting that. In a year-end review to be published shortly in Nature Reviews Clinical Oncology, the SWOG 0777 study is identified as the major “practice changing” trial for 2016.

ASH 2016: A negative study is great news for patients

Among the 688 myeloma-related abstracts presented at the Annual Meeting of the American Society of Hematology (ASH) this year, one stands out. This is “Late-Breaking Abstract: LBA-1,” presented by Dr. Ed Stadtmauer on Tuesday, December 6th at 7:30 am.

Successful iStopMM launch pioneers a new way to manage disease

This week, the iStopMM team launched the ambitious screening, treatment, and prevention program for MGUS, SMM, and MM in Iceland.

ASH 2016: What’s trending and what’s not

The 58th Annual Meeting & Exhibition of the American Society of Hematology is upon us, starting in San Diego on December 3rd and running through December 6th. This year, there are more than 700 myeloma-related presentations, with 114 oral abstracts, and 573 posters covering sessions on Saturday, Sunday, and Monday.

NCCN endorses MRD testing: what does this mean for patients?

NCCN endorses MRD testing: what does this mean for patients?

Pages